Lillian B. Cohn

Lillian B. Cohn

Auto-generated profile, based on publicly available information

Lillian B. Cohn

Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA 98109

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in eLife
Verified
Journal Article
Open access
EBEmilie Battivelli
Emilie Battivelli
MDMatthew S Dahabieh
Matthew S Dahabieh
MAMohamed Abdel-Mohsen
Mohamed Abdel-Mohsen
JSJ Peter Svensson
J Peter Svensson
ISIsrael Silva
Israel Silva
EVEric Verdin
Eric Verdin
Human immunodeficiency virus (HIV) infection is currently incurable, due to the persistence of latently infected cells. The ‘shock and kill’ approach to a cure proposes to eliminate this reservoir via transcriptional activation of latent proviruses, enabling direct or indirect killing of infected cells. Currently available latency-reversing agents (LRAs) have however proven ineffective. To understand why, we used a novel HIV reporter strain in primary CD4+ T cells and determined which latently infected cells are reactivatable by current candidate LRAs. Remarkably, none of these agents reactivated more than 5% of cells carrying a latent provirus. Sequencing analysis of reactivatable vs. non-reactivatable populations revealed that the integration sites were distinguishable in terms of chromatin functional states. Our findings challenge the feasibility of ‘shock and kill’, and suggest the need to explore other strategies to control the latent HIV reservoir.

20 April 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PMPilar Mendoza
Pilar Mendoza
JJJulia R. Jackson
Julia R. Jackson
TOThiago Y. Oliveira
Thiago Y. Oliveira
CGChristian Gaebler
Christian Gaebler
VRVictor Ramos
Victor Ramos
LCLillian B. Cohn
Lillian B. Cohn
Antiretroviral therapy suppresses but does not cure HIV-1 infection due to the existence of a long-lived reservoir of latently infected cells. The reservoir has an estimated half-life of 44 mo and is largely composed of clones of infected CD4+ T cells. The long half-life appears to result in part from expansion and contraction of infected CD4+ T cell clones. However, the mechanisms that govern this process are poorly understood. To determine whether the clones might result from and be maintained by exposure to antigen, we measured responses of reservoir cells to a small subset of antigens from viruses that produce chronic or recurrent infections. Despite the limited panel of test antigens, clones of antigen-responsive CD4+ T cells containing defective or intact latent proviruses were found in seven of eight individuals studied. Thus, chronic or repeated exposure to antigen may contribute to the longevity of the HIV-1 reservoir by stimulating the clonal expansion of latently infected CD4+ T cells.

12 October 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AHAmy S. Huang
Amy S. Huang
VRVictor Ramos
Victor Ramos
TOThiago Y. Oliveira
Thiago Y. Oliveira
CGChristian Gaebler
Christian Gaebler
MJMila Jankovic
Mila Jankovic
LCLillian B. Cohn
Lillian B. Cohn
Latent intact HIV-1 proviruses persist in a small subset of long-lived CD4+ T cells that can undergo clonal expansion in vivo. Expanded clones of CD4+ T cells dominate latent reservoirs in individuals on long-term antiretroviral therapy (ART) and represent a major barrier to HIV-1 cure. To determine how integration landscape might contribute to latency, we analyzed integration sites of near full length HIV-1 genomes from individuals on long-term ART, focusing on individuals whose reservoirs are highly clonal. We find that intact proviruses in expanded CD4+ T cell clones are preferentially integrated within Krüppel-associated box (KRAB) domain–containing zinc finger (ZNF) genes. ZNF genes are associated with heterochromatin in memory CD4+ T cells; nevertheless, they are expressed in these cells under steady-state conditions. In contrast to genes carrying unique integrations, ZNF genes carrying clonal intact integrations are down-regulated upon cellular activation. Together, the data suggest selected genomic sites, including ZNF genes, can be especially permissive for maintaining HIV-1 latency during memory CD4+ T cell expansion.

9 July 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
AFAnna Farrell-Sherman
Anna Farrell-Sherman
NFNatalia de la Force
Natalia de la Force
CPCecilia A Prator
Cecilia A Prator
RVRenan Valieris
Renan Valieris
WAWalker Azam
Walker Azam
LCLillian B Cohn
Lillian B Cohn
The persistence of human immunodeficiency virus 1 (HIV-1) proviruses in latently infected cells allows viremia to resume upon treatment cessation. To characterize the resulting immune response, we compared plasma proteomics and single-cell transcriptomics of peripheral blood mononuclear cells before, during, and after detectable plasma viremia. We observed unique transcriptional signatures prior to viral rebound, including a significant increase in CD16++ monocytes with increased antiviral gene expression. Inflammatory proteins were identified in plasma after detectable rebound. Identifying early signals of imminent viral rebound after treatment cessation will aid in the development of strategies to prolong time to viral rebound and cure HIV-1.

4 January 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
EBEmilie Battivelli
Emilie Battivelli
MDMatthew S. Dahabieh
Matthew S. Dahabieh
MAMohamed Abdel-Mohsen
Mohamed Abdel-Mohsen
JSJ. Peter Svensson
J. Peter Svensson
ISIsrael Tojal Da Silva
Israel Tojal Da Silva
EVEric Verdin
Eric Verdin
Human immunodeficiency virus (HIV) infection cannot be cured due to a small reservoir of latently infected CD4 + T cells in treated patients. The “shock and kill” approach proposes to eliminate the reservoir by inducing its activation and the direct or indirect killing of infected cells. Current latency reversing agents (LRAs) do not reduce the viral reservoir in treated patients. We use a novel dual-fluorescent HIV reporter to identify and purify latent cells, and to determine the fraction of latent cells that undergo viral reactivation after infection of primary CD4 + T cells. Unexpectedly, LRAs reactivate less than 5% of latent proviruses. Analysis of HIV integration sites from induced and non-induced latent populations reveals distinct provirus integration sites between these two populations in terms of chromatin functional states. These findings challenge “shock and kill”, and suggest the need of more potent LRAs in combination with immunomodulatory approaches to eradicate HIV reservoir.

2 July 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MGMauro A. Garcia
Mauro A. Garcia
AFAnna Farrell-Sherman
Anna Farrell-Sherman
BABeril Aydin
Beril Aydin
JZJunlin Zhuo
Junlin Zhuo
EFEmily J Fray
Emily J Fray
JSJanet D. Siliciano
Janet D. Siliciano
HIV-1 cure requires preventing viral rebound after treatment interruption, but quantitative criteria defining the rebound-competent reservoir are lacking. We studied individuals undergoing observational treatment interruption without confounding interventions to identify virologic and immunologic determinants of rebound. In 9 of 13 participants, rebound viruses were genetically identical or similar to proviruses in circulating resting CD4 + T-cells. We found no evidence of recombination among rebound sequences. Instead, resistance to autologous neutralizing antibodies (aNAbs) was a critical determinant of viral rebound. Increased suppression of viral outgrowth by contemporaneous IgG isolated from plasma was correlated with longer time to rebound. Using inhibitory potential ( IP ), the log reduction in single-round infection at physiologic IgG concentrations, we defined quantitative limits governing rebound-competency with respect to contemporaneous aNAbs. Contemporaneous IgG antibodies inhibited different reservoir variants with a wide range of IP values (0.4 to 8.2 logs), whereas rebound viruses were minimally inhibited (0.5 to 2.8 logs), indicating that inhibition by even up to 2.8 logs (631-fold) cannot prevent rebound. Longitudinal analyses revealed that waning aNAb potency over time on antiretroviral therapy (ART) allows previously neutralized variants to gain rebound potential, consistent with the finding that rebound can come from variants deposited in the reservoir at different pre-ART time points. Thus, rebound competency is a dynamic, immune-governed property defined by quantitative immunologic constraints, including those exerted by aNAbs.